{"id":1036436,"date":"2012-07-31T19:21:15","date_gmt":"2012-07-31T19:21:15","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/plandai-biotechnology-announces-that-in-recent-test-results-its-patented-phytofaretm-natural-green-tea-catechins.php"},"modified":"2024-08-17T15:56:24","modified_gmt":"2024-08-17T19:56:24","slug":"plandai-biotechnology-announces-that-in-recent-test-results-its-patented-phytofaretm-natural-green-tea-catechins","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/plandai-biotechnology-announces-that-in-recent-test-results-its-patented-phytofaretm-natural-green-tea-catechins.php","title":{"rendered":"Plandai Biotechnology Announces That in Recent Test Results Its Patented Phytofare(TM) Natural Green Tea &quot;Catechins &#8230;"},"content":{"rendered":"<p><p>    SEATTLE, July 31, 2012 (GLOBE NEWSWIRE) -- Plandai    Biotechnology, Inc. (PLPL),    a producer of highly bioavailable plant extracts, today    announced recent test results support the use of catechins in    preventing the spread of HIV. The report, published in Clinical    Immunology, states that four catechins with the galloyl moiety,    including catechin gallate (CG), epigallocatechin gallate    (EGCG), gallocatechin gallate (GCG), and epicatechin gallate    (ECG), were found to effectively inhibit HIV-1 integrase.    Integrase is the enzyme produced by a virus that allows it to    be integrated into the infected cell. Inhibiting    integrase is seen as a key component in preventing the spread    of retroviruses such as HIV.  <\/p>\n<p>    The study, while recognizing previous research demonstrating    the potential for green tea catechins in preventing HIV, sought    to isolate the operative factors that yielded these results.    The researchers found that the four catechins may bind between    the HIV-1 integrase, thus disrupting its interaction with virus    DNA. The four catechins have a highly cooperative inhibitory    effect, suggesting that catechins with the galloyl moiety could    be a novel and effective class of HIV-1 integrase inhibitors.  <\/p>\n<p>    In 2007 the first HIV-1 integrase target drug, Raltegravir, was    approved by the Food and Drug Administration. While HIV-1    integrase has become an attractive drug target recently,    raltegravir resistance mutations have been found in clinical    trials.  <\/p>\n<p>    Roger Duffield, Chief Executive Officer of Plandai, commented,    \"The recently approved clinical integrase inhibitors are almost    all derived from diketo acid (DKA), a synthetic compound that    selectively inhibits the strand transfer step of integration.    Catechins, however, are natural compounds found in tea    that are well-known for their healthy effects and safety. Thus,    catechins may provide a safe and well-tolerated drug.    Furthermore, catechins are cheap natural compounds. A clinical    dose of our green tea derived catechin extract would be    approximately 700 times cheaper than raltegravir. Thus,    catechins that contain a galloyl moiety may drastically reduce    the prescription cost for HIV-1 patients and may be popular    among low-income populations.\"  <\/p>\n<p>    Plandai Biotechnology's patented highly-bioavailable green tea    extract, Phytofare(TM), is a green tea-based extract rich in    all four catechins and eight times better absorbed by human    tissue.  <\/p>\n<p>    About Plandai Biotechnology, Inc.  <\/p>\n<p>    Plandai Biotechnology, Inc. focuses on the farming of whole    fruits, vegetables and live plant material and the production    of proprietary functional foods and botanical extracts for the    health and wellness industry. Its principle holdings consist of    land, farms and infrastructure in South Africa. Web site:        <a href=\"http:\/\/www.plandaibiotech.com\/\" rel=\"nofollow\">http:\/\/www.plandaibiotech.com\/<\/a>  <\/p>\n<p>    Safe Harbor    Statement  <\/p>\n<p>    The information provided may contain forward-looking statements    and involve risks and uncertainties. Results, events and    performances could vary from those contemplated. These    statements involve risks and uncertainties which may cause    actual results, expressed or implied, to differ from predicted    outcomes. Risks and uncertainties include product demand,    market competition, and Plandai's ability to meet current or    future plans. Investors should study and understand all risks    before making an investment decision. Readers are recommended    not to place undue reliance on forward-looking statements or    information. Plandai is not obliged to publicly release    revisions to any forward-looking statement, to reflect events    or circumstances afterward, or to disclose unanticipated    occurrences, except as required under applicable laws.  <\/p>\n<\/p>\n<p>More:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/plandai-biotechnology-announces-recent-test-133000576.html;_ylt=A2KJ3CQhMBhQjD0A0mb_wgt.\" title=\"Plandai Biotechnology Announces That in Recent Test Results Its Patented Phytofare(TM) Natural Green Tea &quot;Catechins ...\" rel=\"noopener\">Plandai Biotechnology Announces That in Recent Test Results Its Patented Phytofare(TM) Natural Green Tea &quot;Catechins ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SEATTLE, July 31, 2012 (GLOBE NEWSWIRE) -- Plandai Biotechnology, Inc. (PLPL), a producer of highly bioavailable plant extracts, today announced recent test results support the use of catechins in preventing the spread of HIV.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/plandai-biotechnology-announces-that-in-recent-test-results-its-patented-phytofaretm-natural-green-tea-catechins.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-1036436","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036436"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1036436"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036436\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1036436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1036436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1036436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}